TRUALT Q2 FY27 Results & Earnings Analysis
Sentiment: Neutral (Confidence: medium)
Earnings Summary
TruAlt Bioenergy reported strong Q2 FY27 revenue growth of 606% YoY to INR811 crores and a PAT turnaround to INR35 crores, driven by higher ethanol volumes and capacity utilization. However, EBITDA margin contracted sharply QoQ to 14.03% due to a 25-30% rise in maize prices. Management expects margin recovery from Q3 as raw material season improves and CBG plants ramp up. The company is focused on CBG expansion (250 TPD target) and SAF, supported by government policies, while managing raw material volatility and working capital. Key risks include El Nino impact, regulatory changes, and margin pressure.
Management Tone
- Prepared Remarks: Good — Management highlighted strong revenue growth (606% YoY in Q2), a PAT turnaround, healthy operating cash flow, and progress in CBG and SAF initiatives, while acknowledging raw material margin pressure. Overall tone was positive but measured.
- Q&A Session: Neutral — Analysts pressed on margin sustainability, raw material cost pass-through, volume guidance, policy changes, and promoter pledging. Management provided some quantification (e.g., volume, margins) but was cautious on forward margins and evaded some details (e.g., pledge repayment).
Revenue Growth Drivers
- Higher ethanol volume due to additional OMC allocation and Supreme Court judgment
- Improved capacity utilization from ~62% in Q2 to targeted 75-80%
- CBG plant commissioning (20 TPD Sumitomo JV operational, two more by Q3)
Growth vs Margin Focus
Management emphasized revenue growth through volume expansion and CBG, while also focusing on margin recovery through raw material optimization, capacity utilization, and cost control.
About TruAlt Bioenergy Limited
TruAlt Bioenergy Limited (TRUALT) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.